Amgen Inc. (NASDAQ: AMGN) delivered a dual beat Tuesday. The biotech leader surpassed Wall Street expectations for both profit and revenue during the fourth quarter. Investor focus remains locked on the company’s experimental weight-loss treatment as clinical trials accelerate.
Adjusted earnings hit $5.29 per share. Analysts predicted $4.73. Quarterly revenue climbed 9% to reach $9.9 billion, bolstered by strong sales of the cholesterol drug Repatha. Sales for that specific treatment surged 44% to $870 million during the period.
Regulatory friction emerged alongside the financial wins. The U.S. Food and Drug Administration (FDA) requested that Amgen pull its rare disease drug, Tavneos, from the market. The company declined the request. Negotiations with the agency are currently ongoing.
“Amgen delivered strong performance in 2025, with double-digit growth in revenues and earnings per share,” said Chairman and CEO Robert A. Bradway. He noted the firm enters the new year with momentum across its broad portfolio.
Guidance for 2026 looks steady. The company projected total revenue between $37 billion and $38.4 billion. This outlook aligns with market consensus. Research and development spending increased 22% as the firm prioritizes its obesity pipeline and later-stage clinical programs.
Market reaction was muted. Shares dipped 0.38% in after-hours trading despite the earnings surprise. Traders are weighing the potential of the injectable MariTide against the declining sales of older assets like Enbrel, which dropped 48% due to biosimilar competition.
